MOTS-C is the only mitochondrial-derived peptide in the buying guides cluster — a 16-amino-acid mitokine (MRWQEMGYIFYPRKLR, MW ~2,174.6 Da) encoded by mitochondrial DNA, not nuclear DNA, that translocates to the nucleus under metabolic stress to regulate AMPK-mediated energy homeostasis. First described in 2015, it is also one of the newest research peptides on the market — with less manufacturing maturation than any other compound covered in these guides.
This article applies 7 verification checks to MOTS-C using data from Peptigrity's independent lab tests, community reviews, and reviewed peptide shops. Peptigrity does not sell peptides or recommend vendors.
What Is MOTS-C and Why Is It Unlike Any Other Research Peptide?
MOTS-C (Mitochondrial Open Reading Frame of the 12S rRNA type-c) is a 16-amino-acid peptide encoded within the 12S rRNA gene of mitochondrial DNA — the only peptide in the buying guides cluster derived from the mitochondrial genome rather than nuclear DNA — acting as a mitokine that signals from mitochondria to nucleus to regulate metabolic homeostasis.
The landmark discovery: Lee et al. (2015, Cell Metabolism) identified MOTS-C as a mitochondrial-derived peptide (MDP) that activates the AMPK pathway in skeletal muscle, enhancing glucose uptake, fatty acid oxidation, and mitochondrial biogenesis. In mice, MOTS-C prevented high-fat diet-induced obesity and insulin resistance through AMPK activation. Circulating MOTS-C levels decline with age in humans — a pattern consistent with age-related metabolic deterioration.
The mechanism is genuinely novel. Unlike receptor-mediated peptides (GLP-1 agonists binding GLP-1R, GH secretagogues binding GHSR), MOTS-C operates through intracellular signalling. Under metabolic stress, it translocates from mitochondria into the nucleus where it regulates nuclear gene expression — activating pathways including AMPK, PGC-1α (mitochondrial biogenesis), and Nrf2 (antioxidant defence). This mitochondria-to-nucleus retrograde signalling is a fundamentally different mechanism from any other compound in the buying guides cluster.
Exercise mimetic properties: MOTS-C plasma levels increase during exercise in humans. Exogenous MOTS-C improved physical performance in aged mice — positioning it as one of the few peptides studied in the context of exercise-induced metabolic adaptation.
No human clinical trials have been completed as of March 2026. No FDA approval. Not on Category 2. Not currently WADA-prohibited. Sequence: MRWQEMGYIFYPRKLR. CAS: 1627580-64-6.
MOTS-C-Specific Buying Risks
MOTS-C carries 3 buying risks specific to its chemistry and novelty: dual methionine oxidation susceptibility, limited manufacturing optimisation for a compound described only in 2015, and high dosing protocols that amplify the impact of batch-to-batch quality variance.
Dual methionine oxidation. MOTS-C contains 2 methionine residues (Met1 and Met6). Methionine oxidises to methionine sulfoxide under heat, light, or improper storage — producing a biologically altered peptide. Each oxidised Met adds ~16 Da to the molecular weight. HPLC detects oxidised variants as additional peaks near the main peak. BPC-157 has 1 methionine and the same oxidation concern — MOTS-C has the risk doubled. Prompt freezer storage on arrival is more important for MOTS-C than for Met-free peptides.
Manufacturing novelty. MOTS-C was described only in 2015 — the newest compound in the buying guides cluster. Fewer synthesis laboratories have optimised its production compared to established compounds. The 16-amino-acid sequence includes 2 tryptophan residues (Trp3) that are notoriously difficult to couple during solid-phase peptide synthesis, contributing to medium-high synthesis complexity.
High dosing amplifies quality variance. Research protocols often use 5–10 mg per day — compared to 200–250 mcg for ipamorelin or BPC-157. Buyers consume product 20–50× faster, going through more vials per protocol. Each vial represents an independent quality event. Batch-to-batch consistency matters more for high-dose compounds because quality variance accumulates across more units.
7 Things to Check Before Ordering MOTS-C
The same 7 checks apply — with MOTS-C, pay particular attention to methionine oxidation (HPLC secondary peaks near the main peak) and batch-to-batch consistency (high dosing protocols mean you'll go through multiple vials).
1. Third-Party HPLC Purity (≥98%)
HPLC detects methionine sulfoxide variants that oxidation produces — appearing as secondary peaks near the main MOTS-C peak. A clean single main peak is essential. Secondary peaks in the immediate vicinity of the main peak may indicate Met1 or Met6 oxidation. Cross-reference on peptigrity.com/lab-tests — filter by "MOTS-C." The study "Peptide Impurities in Commercial Synthetic Peptides" (PMC2238048) demonstrated that contamination at 1% produced measurable biological effects — for a peptide with oxidation-sensitive residues, this threshold is directly relevant.
2. Mass Spectrometry Identity (~2,174.6 Da)
MS confirms the compound is MOTS-C. The MW ~2,174.6 Da is distinctive — no common research peptide shares this exact mass. MS also detects oxidation: if the observed MW is ~2,190 Da (+16, single Met oxidised) or ~2,206 Da (+32, both Met residues oxidised), the product has undergone oxidative degradation. See Mass Spectrometry for Peptides: Verifying Identity & Molecular Weight for the methodology.
3. CoA From a Named, Verifiable Lab
Verify through the lab's portal: Janoshik (Task #), Chromate (QR code + Job Number), Freedom Diagnostics (online system). For MOTS-C: check whether the CoA addresses methionine oxidation status. A CoA that reports purity without mentioning oxidation is incomplete for a dual-Met peptide. See Red Flags in Peptide Certificates of Analysis for the fraud detection checklist.
4. Independent Data on Peptigrity
Search peptigrity.com/lab-tests for the vendor + MOTS-C. Check the shop's profile on peptigrity.com/shops — trust score, ✓ Lab Verified badge, and test count. For a compound you'll purchase repeatedly at high doses, vendor consistency across multiple batches is more valuable than a single test result.
5. Community Reviews
Read reviews on the vendor's Peptigrity page. Each includes 5 sub-ratings: Quality, Delivery, Pricing, Customer Service, and Product Accuracy. MOTS-C buyers use the compound at higher doses than most peptides — look for mentions of batch consistency across multiple orders, not just single-purchase impressions.
6. Vial Presentation and Storage
Lyophilised MOTS-C should be a white to off-white powder. Not lipidated, but methionine-sensitive to oxidation. Most RUO vendors ship at ambient temperature — for 2–5 day domestic transit of lyophilised powder, this is acceptable. Store at −20°C immediately on arrival. Protect from light. The 2 methionine residues make prompt freezer storage more important than for Met-free peptides. After reconstitution: 2–8°C, use within 28 days. Do not freeze reconstituted MOTS-C.
7. Pricing Reality Check
Research-grade MOTS-C pricing (March 2026):
5 mg vial: $40–80.
10 mg vial: $60–130.
More expensive per mg than Epitalon (4 AA) or ipamorelin (5 AA) — 16 amino acids with 2 tryptophan residues represents harder synthesis. Below $25 for 10 mg is suspicious. At research dosing of 5–10 mg/day, cost per protocol adds up quickly — compare across vendors on Peptigrity before committing to a multi-vial purchase. See Peptide Purity Standards: What Percentage Is Actually Acceptable? for the quality-price framework.
MOTS-C on Peptigrity's Lab Test Database
Filter by MOTS-C at peptigrity.com/lab-tests to compare independent purity data across vendors before ordering.
Community-submitted data from third-party laboratories represents real products from real buyers. For a high-dose compound where you will purchase multiple vials, comparing purity data across vendors before your first order prevents committing to a vendor with inconsistent quality. Browse the MOTS-C peptide guide for the compound profile alongside lab data.
Frequently Asked Questions
What purity should research-grade MOTS-C have?
≥98% HPLC from a third-party lab. For MOTS-C specifically, check HPLC for methionine sulfoxide peaks — oxidation of Met1 or Met6 produces biologically altered variants detectable as secondary peaks. MS confirms oxidation via +16 Da (single Met) or +32 Da (both Met) shifts. Cross-reference on peptigrity.com/lab-tests.
How much does research-grade MOTS-C cost?
$40–80 for 5 mg, $60–130 for 10 mg. More expensive per mg than Epitalon or ipamorelin due to 16-amino-acid synthesis complexity. Below $25 for 10 mg is suspicious. At 5–10 mg/day research dosing, cost per protocol adds up — compare across vendors on peptigrity.com/shops.
What is MOTS-C and where does it come from?
MOTS-C is a 16-amino-acid peptide encoded by mitochondrial DNA — first described by Lee et al. in 2015 (Cell Metabolism). It is a mitokine: a signalling molecule that translocates from mitochondria to the nucleus under metabolic stress, activating AMPK-mediated energy homeostasis. The only mitochondrial-derived peptide in the buying guides cluster.
Is MOTS-C FDA-approved?
No. No human clinical trials have been completed. Not on FDA Category 2. Not currently WADA-prohibited. Available only as a research compound from RUO vendors.
Why does MOTS-C need special storage attention?
MOTS-C contains 2 methionine residues (Met1, Met6) that oxidise under heat, light, or improper storage. Store lyophilised at −20°C, protected from light, immediately on arrival. After reconstitution: 2–8°C, use within 28 days. Prompt freezer storage is more important for MOTS-C than for Met-free peptides.
For the complete buyer verification framework, see How to Verify Peptide Quality Before You Buy and What to Look for in a Peptide Shop: A Buyer's Checklist. Browse all peptide shops ranked by trust score.
This article is for educational and informational purposes only and does not constitute medical advice. MOTS-C is a research compound not approved by the FDA for human use. No human clinical trials have been completed as of 2026. Research-grade peptides have no mandatory manufacturing standards. Always consult a qualified healthcare provider before using any peptide or research compound. Peptigrity is an independent review platform and does not sell, endorse, or recommend specific products or vendors.
